Skip to main
TOI

TOI Stock Forecast & Price Target

TOI Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

The Oncology Institute Inc. (TOI) is expecting significant margin improvements in 2026 and 2027 due to its partnership with Helios, which will enhance operational efficiencies and contribute to overall profitability. The company has demonstrated strong year-over-year growth rates of 24%, 28%, and 21% for the years 2022, 2023, and 2024 as it expanded its clinic management from 67 to 86 locations, indicating effective scaling and market penetration. Additionally, the growing oncology market, projected at over $200 billion with a CAGR exceeding 10%, coupled with TOI's robust expansion in high-value markets like Nevada and Florida, positions the company for sustained revenue growth and margin enhancement in the future.

Bears say

The Oncology Institute Inc. is experiencing significant challenges, with HUM's contribution to revenue plummeting from 20% to less than 10%, indicating a loss of a substantial revenue stream. Additionally, contract losses in 2024 have adversely affected gross margins, and the elimination of DIR fees resulted in a $15 million headwind for dispensary margins, raising concerns about profitability. Furthermore, despite an industry trend growth of 11-14%, TOI's anticipated revenue growth is stagnating, projected to remain flat or in low single digits, compounding the negative outlook for the company's financial performance.

TOI has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Oncology Institute (TOI) Forecast

Analysts have given TOI a Strong Buy based on their latest research and market trends.

According to 3 analysts, TOI has a Strong Buy consensus rating as of Jan 10, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Oncology Institute (TOI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.